CASP4 and carcinoma: TRAMP mice aged to 26-weeks harbouring the tx mutation have a remarkable reduction in both prostate cancer burden (64% reduction) (Figure 5A) and disease severity (grade), with no discernable carcinoma development (Figure 5B).